Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects. / Westberg-Rasmussen, Sidse; Starup-Linde, Jakob; Hermansen, Kjeld; Holst, Jens Juul; Hartmann, Bolette; Vestergaard, Peter; Gregersen, Søren.

In: Bone, Vol. 97, 04.2017, p. 261-266.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Westberg-Rasmussen, S, Starup-Linde, J, Hermansen, K, Holst, JJ, Hartmann, B, Vestergaard, P & Gregersen, S 2017, 'Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects', Bone, vol. 97, pp. 261-266. https://doi.org/10.1016/j.bone.2017.01.027

APA

Westberg-Rasmussen, S., Starup-Linde, J., Hermansen, K., Holst, J. J., Hartmann, B., Vestergaard, P., & Gregersen, S. (2017). Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects. Bone, 97, 261-266. https://doi.org/10.1016/j.bone.2017.01.027

Vancouver

Westberg-Rasmussen S, Starup-Linde J, Hermansen K, Holst JJ, Hartmann B, Vestergaard P et al. Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects. Bone. 2017 Apr;97:261-266. https://doi.org/10.1016/j.bone.2017.01.027

Author

Westberg-Rasmussen, Sidse ; Starup-Linde, Jakob ; Hermansen, Kjeld ; Holst, Jens Juul ; Hartmann, Bolette ; Vestergaard, Peter ; Gregersen, Søren. / Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects. In: Bone. 2017 ; Vol. 97. pp. 261-266.

Bibtex

@article{e217689c43b84128a139cfb10eebe46c,
title = "Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects",
abstract = "BACKGROUND: Patients with type-1 (T1D) and type-2 diabetes mellitus (T2D) have an increased risk of hip fracture. The underlying mechanisms may involve disturbances in the incretin hormones. Our aim was to clarify if glucose administration i.e. orally or intravenously differentially affects bone turnover markers in healthy males.METHODS: 12 healthy males were included in a cross-over study consisting of three tests following an 8hour fast. First, an oral glucose tolerance test (OGTT) was performed. Subsequently, we carried out an isoglycemic intravenous glucose infusion (IIGI) that closely mimicked the glucose response curve to the oral glucose load. We analyzed blood samples for the bone turnover markers serum C-terminal telopeptide of type I collagen (s-CTX) and serum procollagen type I N propeptide (s-P1NP), as well as insulin, glucose, gastric inhibitory peptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2). Finally, eight of the twelve participants underwent a control experiment where they fasted for 3h (Control).RESULTS: While OGTT induced a 50{\%} reduction in s-CTX, only a ~30{\%} reduction was seen during the IIGI and the Control. Neither intervention influenced s-P1NP. The concentration of insulin was highest during the OGTT. However, insulin was also increased significantly during the IIGI compared to the Control. Plasma concentrations of GIP, GLP-1 and GLP-2 were higher under the OGTT than during the IIGI and Control. A linear regression indicated that peak p-GIP significantly predicts nadir s-CTX (p=0.03), and that peak p-GIP could explain 34{\%} of the variability in nadir s-CTX (adjusted R(2)=0.34).CONCLUSION: This study indicates that glucose per se does not acutely affect bone turnover markers. However, gastrointestinal hormones, especially GIP, possibly in combination with hyperglycemia, may have an acute, uncoupling effect on bone turnover leading to a decrease in bone resorption but no change in bone formation.",
keywords = "Journal Article",
author = "Sidse Westberg-Rasmussen and Jakob Starup-Linde and Kjeld Hermansen and Holst, {Jens Juul} and Bolette Hartmann and Peter Vestergaard and S{\o}ren Gregersen",
note = "Copyright {\circledC} 2017 Elsevier Inc. All rights reserved.",
year = "2017",
month = "4",
doi = "10.1016/j.bone.2017.01.027",
language = "English",
volume = "97",
pages = "261--266",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects

AU - Westberg-Rasmussen, Sidse

AU - Starup-Linde, Jakob

AU - Hermansen, Kjeld

AU - Holst, Jens Juul

AU - Hartmann, Bolette

AU - Vestergaard, Peter

AU - Gregersen, Søren

N1 - Copyright © 2017 Elsevier Inc. All rights reserved.

PY - 2017/4

Y1 - 2017/4

N2 - BACKGROUND: Patients with type-1 (T1D) and type-2 diabetes mellitus (T2D) have an increased risk of hip fracture. The underlying mechanisms may involve disturbances in the incretin hormones. Our aim was to clarify if glucose administration i.e. orally or intravenously differentially affects bone turnover markers in healthy males.METHODS: 12 healthy males were included in a cross-over study consisting of three tests following an 8hour fast. First, an oral glucose tolerance test (OGTT) was performed. Subsequently, we carried out an isoglycemic intravenous glucose infusion (IIGI) that closely mimicked the glucose response curve to the oral glucose load. We analyzed blood samples for the bone turnover markers serum C-terminal telopeptide of type I collagen (s-CTX) and serum procollagen type I N propeptide (s-P1NP), as well as insulin, glucose, gastric inhibitory peptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2). Finally, eight of the twelve participants underwent a control experiment where they fasted for 3h (Control).RESULTS: While OGTT induced a 50% reduction in s-CTX, only a ~30% reduction was seen during the IIGI and the Control. Neither intervention influenced s-P1NP. The concentration of insulin was highest during the OGTT. However, insulin was also increased significantly during the IIGI compared to the Control. Plasma concentrations of GIP, GLP-1 and GLP-2 were higher under the OGTT than during the IIGI and Control. A linear regression indicated that peak p-GIP significantly predicts nadir s-CTX (p=0.03), and that peak p-GIP could explain 34% of the variability in nadir s-CTX (adjusted R(2)=0.34).CONCLUSION: This study indicates that glucose per se does not acutely affect bone turnover markers. However, gastrointestinal hormones, especially GIP, possibly in combination with hyperglycemia, may have an acute, uncoupling effect on bone turnover leading to a decrease in bone resorption but no change in bone formation.

AB - BACKGROUND: Patients with type-1 (T1D) and type-2 diabetes mellitus (T2D) have an increased risk of hip fracture. The underlying mechanisms may involve disturbances in the incretin hormones. Our aim was to clarify if glucose administration i.e. orally or intravenously differentially affects bone turnover markers in healthy males.METHODS: 12 healthy males were included in a cross-over study consisting of three tests following an 8hour fast. First, an oral glucose tolerance test (OGTT) was performed. Subsequently, we carried out an isoglycemic intravenous glucose infusion (IIGI) that closely mimicked the glucose response curve to the oral glucose load. We analyzed blood samples for the bone turnover markers serum C-terminal telopeptide of type I collagen (s-CTX) and serum procollagen type I N propeptide (s-P1NP), as well as insulin, glucose, gastric inhibitory peptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2). Finally, eight of the twelve participants underwent a control experiment where they fasted for 3h (Control).RESULTS: While OGTT induced a 50% reduction in s-CTX, only a ~30% reduction was seen during the IIGI and the Control. Neither intervention influenced s-P1NP. The concentration of insulin was highest during the OGTT. However, insulin was also increased significantly during the IIGI compared to the Control. Plasma concentrations of GIP, GLP-1 and GLP-2 were higher under the OGTT than during the IIGI and Control. A linear regression indicated that peak p-GIP significantly predicts nadir s-CTX (p=0.03), and that peak p-GIP could explain 34% of the variability in nadir s-CTX (adjusted R(2)=0.34).CONCLUSION: This study indicates that glucose per se does not acutely affect bone turnover markers. However, gastrointestinal hormones, especially GIP, possibly in combination with hyperglycemia, may have an acute, uncoupling effect on bone turnover leading to a decrease in bone resorption but no change in bone formation.

KW - Journal Article

U2 - 10.1016/j.bone.2017.01.027

DO - 10.1016/j.bone.2017.01.027

M3 - Journal article

C2 - 28126633

VL - 97

SP - 261

EP - 266

JO - Bone

JF - Bone

SN - 8756-3282

ER -

ID: 174401502